Parathyroid tumorigenesis

Clinical Cases in Mineral and Bone Metabolism

Volumn 3, Issue 2, 2006, Pages 123-131

  Cetani, Filomena ^a   Pardi, Elena ^a   Borsari, Simona ^a   Lemmi, Monica ^a   Ambrogini, Elena ^a   Vignali, Edda ^a   Cianferotti, Luisella ^a   Pinchera, Aldo ^a   Marcocci, Claudio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CASR; Cyclin D1; Familial hyperparathyroidism; FIHP; HRPT2; MEN1; Menin; Parafibromin; Parathyroid carcinoma

Indexed keywords

INSULIN; PARATHYROID HORMONE;

CARCINOGENESIS; CHROMOSOME 11Q; FAMILIAL DISEASE; GENE MUTATION; HUMAN; HYPERCALCEMIA; HYPOCALCIURIA; INSULIN BLOOD LEVEL; JAW TUMOR; MULTIPLE ENDOCRINE NEOPLASIA; NEWBORN DISEASE; NONHUMAN; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID TUMOR; PARATHYROIDECTOMY; PATHOGENESIS; PRIMARY HYPERPARATHYROIDISM; SHORT SURVEY; SIPPLE SYNDROME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 33845271480     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (83)

1. Brown EM. Four parameter model of the sigmoidal relationship between parathyroid hormone relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parameter. J Clin Endocrinol Metab. 1983;56:572-581.
2. Parfitt AM. Parathyroid growth: Normal and abnormal. In: Bilezikian JP, ed. The parathyroids: Basic and clinical concepts. 2nd ed. New York: Plenum. 2001:293-329.
3. Haber D, Harlow E. Tumor-suppressor genes: Evolving definitions in the genomic age. Nat Genet. 1997;16:320-322.
4. Tomlinson IP, Roylance R, Houlston RS. Two hits revisited again. J Med Genet. 2001;38:81-85.
5. Chow M, Rubin H. Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res. 2000;60:6510-6518.
6. Jackson CE, Cerny JC, Block MA, et al. Probable clonal origin of aldosteronomas versus multicellular origin of parathyroid "adenoma". Surgery. 1892;95:875-879.
7. Fialkow PJ, Jackson CE, Block MA, et al. Multicellular origin of parathyroid adenomas. N Engl J Med. 1977;297:696-698.
8. Arnold A, Staunton CE, Kim HG, et al. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med. 1988;318:658-662.
9. Tahara H, Smith AP, Gaz RD, et al. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 1996;56:599-605.
10. Agarwal SK, Schrock E, Kester MB, et al. Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet. 1998;106:30-36.
11. Falchetti A, Bale A, Amorosi A, et al. Progression of uremic hyperparathyroidism involves allelic loss on chromosome. J Clin Endocrinol Metab. 1993;76:139-144.
12. Arnold A, Kim HG, Gaz RD, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 1989;83:2034-2040.
13. Rosenberg CL, Kim HG, Shows TB, et al. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene. 1991;6:449-453.
14. Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332:85-87.
15. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science. 1997;276:404-407.
16. MEN-1 TECo The search for the MEN1 gene. The European Consortium on MEN-1. J Intern Med. 1998 243:441-446.
17. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671.
18. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumors. Nat Genet. 1997;16:375-378.
19. Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of non familial primary hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:2960-2963.
20. Farnebo F, Teh BT, Kitola S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 1998;83:2627-2630.
21. Cetani F, Pardi E, Giovannetti A, et al. Six novel mutations in sporadic parathyroid tumors. Hum Mut. 2000;16:445.
22. Goebel Su, Heppner C, Burns AL, et al. Genotype/phenotype correlation of MEN1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab. 2000;85:116-123.
23. Pack S, Turner ML, Zhuang Z, et al. Cutaneous tumors in patients with MEN1 show allelic deletion of the MEN1 gene. J Invest Dermatol. 1998;11:438-440.
24. Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in MEN1. J Clin Endocrinol Metab. 2001;75:76-81.
25. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD activated transcription. Cell. 1999;96:1423-152.
26. Kaji H, Canaff L, Lebrun JJ, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci USA. 2001;98:3837-3842.
27. Agarwal SK, Kennedy PA, Scacheri PC, et al. Menin molecular interaction: insight into normal functions and tumorigenesis. Horm Metab Res. 2005;37:369-374.
28. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of MEN1 develops multiple endocrine tumors. Proc Natl Acad Sci USA. 2001;98:1118-1123.
29. Bertolino P, Tong W, Galendo D, et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003;17:1880-1892.
30. Milligan L, Ponder B. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1995;80:1989-1995.
31. Pausova Z, Soliman E, Amizuka N, et al. Role of the RET protooncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1996;81:2711-2718.
32. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation Consortium analysis. JAMA. 1996;276:1575-1579.
33. Mulligan LM, Eng C, Attie T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994;3:2163-2167.
34. Padberg BC, Schroder S, Jochum W, et al. Absence of RET protooncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol. 1995;147:1600-1607.
35. Williams GH, Rooney S, Carss A, et al. Analysis of the RET protooncogene in sporadic parathyroid adenomas. J Pathol. 1996;180:138-141.
36. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw-tumor syndrome. Nat Genet. 2002;32:676-680.
37. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet. 2003;40:657-663.
38. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New Engl J Med. 2003;349:1722-1729.
39. Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89:5583-5591.
40. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005;612-620.
41. Simonds WF, James-Newton, LA, Agarwal S, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore). 2002;81:1-26.
42. Warner J, Epstein M., Sweet A., et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004;41:155-160.
43. Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96-102.
44. Villablanca A., Calender A, Forsberg L, et al. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004;41:e32.
45. Fujimori, M., Shirahama S, Sakurai A, et al. Novel V184E MEN1 germline mutation in a Japanese kindred with familial hyperparathyroidism. Am J Med Genet. 1998;80:221-222.
46. The BT, Kytola S, Farnebo F, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:2621-2626.
47. Kassem M, Kruse TA, Wong FK, et al. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000;85:165-167.
48. Cetani F, Pardi E, Giovanetti A, et al. Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clin.Endocrinol (Oxf). 2002;56:457-464.
49. Villablanca A, Wassif WS, SmithT, et al. Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol. 2002;147:313-322.
50. Pannett AA, Kennedy AM, Turner JJ, et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin.Endocrinol (Oxf). 2003;58:639-646.
51. Teh BT, Esapa CT, Houlston R, et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet. 1998;63:1544-1549.
52. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004;41:155-160.
53. Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96-102.
54. Villablanca A, Calender A, Forsberg L, et al. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004;41:e32.
55. Cetani F, Pardi E, Ambrogini E, et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol. 2006;64:146-152.
56. Houlston R, Crabtree M, Phillips R, et al. Explaining differences in the severity of familial adenomatous polyposis and the search for modifier genes. Gut. 2001;48:1-5.
57. Foley TP, Harrison HC, Arnaud CD, et al. Familial benign hypercalcemia. J Pediatr. 1972;81:1060-1067.
58. Marx SJ, Spiegel AM, Brown EM, et al. Family studies in patients with primary parathyroid hyperplasia. Am J Med. 1977;62:698-706.
59. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology: a review. Crit Rev Clin Lab Sci. 2005;42:35-70.
60. Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+) sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;31:1237-1239.
61. Heath H III, Jackson CE, Otterud B, et al. Genetic linkage analysis in familial benign hypocalciuric hypercalcemia: Evidence for locus heterogeneity. Am J Hum Genet. 1993;53:193-200.
62. Lloyd S, Pannett AA, Dixon PH, et al. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOK), to chromosome 19q13. Am J Hum Genet. 1999;64:189-195.
63. Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab. 2000;85:2042-2047.
64. Ho C, Conner DA, Pollak MB, et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nature Genet. 1995;11:389-394.
65. Arnold A, Kim HG, Gaz RD, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 1989;83:2034-2040.
66. Rosemberg CI, Kim HG, Shows TB, et al. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene. 1991;6:449-453.
67. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by bcl1-linked candidate oncogene. Nature. 1991;350:512-515.
68. Fu M, Wang C, Li Z, et al. Minireview: Cyclin D1. Normal and abnormal functions. Endocrinol. 2004;145:5439-5447.
69. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
70. Hsi ED, Zukerberg LR, Yang WI, et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736-1739.
71. Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study. Mod Pathol. 1999;12:412-416.
72. Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest. 2001;107:1093-1102.
73. Mallya SM, Gallagher JJ, Yvette K, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol. 2005;19:2603-2609.
74. Hosokawa Y, Pollak MR, Brown EM, et al. Mutational analysis of the extracellular Ca2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab. 1995;80:3107-3110.
75. Cetani F, Pinchera A, Pardi E, et al. No evidence for mutation in the calcium-sensing receptor gene in sporadic parathyroid adenoma. J Bone Miner Res. 1999;14:878-882.
76. Schanz A, Castelman B. Parathyroid carcinoma. Cancer. 1973;31:600-605.
77. Shane E. Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;2:485-493.
78. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor suppressor-gene in parathyroid carcinoma. N Eng J Med. 1994;330:757-761.
79. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol. 2004;60:99-106.
80. Shattuck TN, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumor suppressor genes in parathyroid carcinoma. Clin Endocrinol. 2003;59:180-188.
81. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629-6637.
82. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2005;90:5015-5017.
83. Rubin MR, Silverberg SJ. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. J Clin Endocrinol Metab. 2005;90:5505-5507.